Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple solid tumors
- Trial result
Multiple solid tumors
KVA12123, a Novel Anti-VISTA Antibody, Shows Promising Safety and Signs of Efficacy in Advanced Solid Tumors
In the first-in-human Phase 1 VISTA-101 trial, KVA12123—administered alone and with pembrolizumab—demonstrated a favorable safety profile (no dose-limiting toxicities or cytokine release syndrome) across doses up to…
- Trial result
Multiple solid tumors
FMT Enhances Immunotherapy Response While Influencing Toxicity Profiles in Lung Cancer and Melanoma
In the FMT-LUMINATE trial, patients with advanced NSCLC receiving ⍺PD-1 and melanoma patients treated with dual ICI underwent fecal microbiota transplantation (FMT) from healthy donors, resulting in high objective…
- Trial result
Multiple solid tumors
First-in-Human WRN Inhibitor RO7589831 Shows Promise in Hard-to-Treat MSI/dMMR Cancers
In this Phase 1 trial, RO7589831—a novel, covalent Werner helicase inhibitor—was administered orally at doses from 150 mg to 2000 mg in 44 patients with MSI/dMMR advanced solid tumors, including colorectal, ovarian,…
- Trial result
Multiple solid tumors
ANK-101 Anchored IL-12 Conjugate Elicits Local Immune Activation and Durable Disease Control in Advanced Solid Tumors
In this first-in-human Phase 1 study of ANK-101—an IL-12 conjugated to aluminum hydroxide—administered in a dose-escalation design in heavily pretreated patients with accessible advanced solid tumors, the treatment…
- Trial result
Multiple solid tumors
AMG 404, a New PD-1 Inhibitor, Advances in Early-Phase Trials for Advanced Solid Tumors
In this first-in-human Phase I study of AMG 404, administered every 4 weeks at escalating doses (240, 480, and 1050 mg) across 168 treated patients, the drug demonstrated no dose-limiting toxicities,…
- New trial
Multiple solid tumors
DLL3-Targeting Theranostic Agent Explored in High-grade Neuroendocrine Cancers
Memorial Sloan Kettering is evaluating the safety of 177Lu-DTPA-SC16.56 for relapsed, advanced small-cell lung and neuroendocrine prostate cancers. This study leverages PET/CT imaging to determine the theranostic…
NCT06941480 - New trial
Multiple solid tumors
Intraoperative PET-CT Enhances Margin Visualization in Solid Tumor Resections
Vanderbilt-Ingram Cancer Center is exploring the use of 18F-FDG and the XEOS Aura 10 PET/CT device for high-resolution, ex vivo imaging of resection margins during standard surgical procedures. This technique aims to…
NCT06915454 - New trial
Multiple solid tumors
Phase 1a/1b Trial of BBO-11818 in Advanced KRAS Mutant Cancers
BridgeBio Oncology is conducting a first-in-human study to assess the safety, pharmacokinetics, and preliminary antitumor activity of BBO-11818—a pan-KRAS inhibitor—in advanced, unresectable, or metastatic KRAS…
NCT06917079 - New trial
Multiple solid tumors
Phase 1/2 Trial Evaluates INBRX-106 with Pembrolizumab in Advanced Solid Tumors
Inhibrx Biosciences is launching an open-label, multi-part study to determine the safety, maximum tolerated dose, and potential antitumor activity of INBRX-106—an OX40-targeted agonist protein—administered alone or…
NCT04198766 - New trial
Multiple solid tumors
First-in-Human Study of DS-1471a in Advanced Solid Tumors
Daiichi Sankyo is conducting a phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DS-1471a—a CD147-directed monoclonal antibody—in patients with advanced or metastatic…
NCT06074705 - New trial
Multiple solid tumors
PULSO Trial: Evaluating Pulsed Low-Dose-Rate Radiation for Esophageal Cancer
The Medical College of Wisconsin is running a phase 2 randomized trial comparing pulsed low-dose-rate radiation to standard chemoradiation in patients with advanced/metastatic esophageal cancer. Both arms include…
NCT06906887 - New trial
Multiple solid tumors
Phase 1 Study Evaluates HCB301 in Advanced Solid Tumors and Refractory cHL
FBD Biologics is assessing the safety, pharmacokinetics, and preliminary efficacy of HCB301 administered via IV across escalating doses (0.3 to 15.0 mg/kg) in patients with advanced solid tumors or…
NCT06487624 - New trial
Multiple solid tumors
Pilot Study Evaluates 68Ga-FAPI-46 PET/CT for Tumor Microenvironment Assessment
Vanderbilt University is conducting a pilot study in solid tumor patients scheduled for antibody-based therapy to compare 68Ga-FAPI-46 PET/CT imaging with standard MRI/CT scans. This trial involves a single IV dose…
NCT06922825 - New trial
Multiple solid tumors
Phase 1b/2 Study Evaluates WTX-330 Dosing Regimens in Advanced Solid Tumors and NHL
Werewolf Therapeutics is assessing WTX-330, an IL-12 peptide prodrug, using both fixed and step-up dosing regimens in a multisite study targeting advanced/metastatic solid tumors and non-Hodgkin lymphoma. The trial…
NCT06939283 - New trial
Multiple solid tumors
Phase I/II Study Explores MT-4561 in Advanced Solid Tumors and Drug-Drug Interaction
Mitsubishi Tanabe Pharma America is launching a first-in-human, open-label study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-4561 in patients with various advanced solid…
NCT06943521 - New trial
Multiple solid tumors
Phase 1/2 Trial Evaluates Neratinib Plus Valproic Acid in Advanced Solid Tumors with RAS Focus
Virginia Commonwealth University is testing a combination of neratinib—a HER2/HER4/EGFR inhibitor—and divalproex sodium in advanced solid tumors, with particular attention to RAS-mutated cancers, EGFR-altered…
NCT03919292 - New trial
Multiple solid tumors
Phase 1a/1b Trial Investigates Intrathecal Deferoxamine for Leptomeningeal Metastases
Memorial Sloan Kettering is evaluating the safety, pharmacokinetics, and pharmacodynamics of intrathecal deferoxamine in patients with leptomeningeal metastases from solid tumors, including NSCLC. This open-label,…
NCT05184816 - New trial
Multiple solid tumors
Perioperative Chemoimmunotherapy with Toripalimab for Sinonasal Cancer
Dana Farber is investigating a novel perioperative regimen combining toripalimab with docetaxel and carboplatin preceding surgery for resectable sinonasal cancers, including undifferentiated carcinoma and squamous…
NCT06940180 - New trial
Multiple solid tumors
Phase 1/2 Trial Assesses Inhaled Oncolytic Virus KB707 in Lung Cancer
Krystal Biotech is evaluating KB707—a replication-defective, HSV-1-derived vector expressing IL-2 and IL-12—administered via nebulization in advanced solid tumor malignancies affecting the lungs. The study includes…
NCT06228326 - New trial
Multiple solid tumors
Phase I/II Study of 225Ac-SSO110 Combined with SoC in SSTR2+ ES-SCLC and Merkel Cell Carcinoma
Ariceum Therapeutics is investigating the safety, tolerability, RP2D, and preliminary efficacy of 225Ac-SSO110 in combination with standard of care—including checkpoint inhibitors and chemotherapy—in patients with…
NCT06939036 - New trial
Multiple solid tumors
Phase I/II Trial Evaluates DM002 in Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) is conducting a first-in-human, open-label study to assess the safety, pharmacokinetics, and preliminary efficacy of DM002 in advanced solid tumors. The study features a…
NCT06751329 - New trial
Multiple solid tumors
Phase 1 Trial Investigates MRTX1719 in MTAP-Deleted Advanced Solid Tumors
Bristol-Myers Squibb is conducting an open-label, multicenter study to assess the safety, PK/PD, and antitumor activity of MRTX1719—a PRMT5 inhibitor—in patients with unresectable or metastatic solid tumors harboring…
NCT06937970
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.